“…The serotonin 5-HT 1 receptor agonist sumatriptan and the other so-called triptans are selective and effective therapies for the acute treatment of migraine pain (Bigal et al, 2009; Moskowitz and Cutrer, 1993; Sprenger and Goadsby, 2009; Tfelt-Hansen et al, 2000; Tfelt-Hansen and Koehler, 2011). However, despite the success of the triptans in the clinical setting, the anatomical locus of their antimigraine activity remains unresolved, and both peripheral and central nervous system sites of action are likely (Ahn and Basbaum, 2005; Akerman et al, 2011; Bartsch et al, 2004; Durham and Russo, 2002; Humphrey and Feniuk, 1991; Lambert, 2010; Levy et al, 2004; Mehrotra et al, 2008; Tfelt-Hansen, 2010).…”